Paragon Associates & Paragon Associates II Joint Venture’s AbbVie ABBV Stock Holding History

Paragon Associates & Paragon Associates II Joint Venture’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-60,000	Closed	-$5.89M	–	9
2020 Q2	$5.89M	Buy	+60,000	New	+$5.28M	6.47%	5
2020 Q1	–	Sell	-150,000	Closed	-$13.3M	–	14
2019 Q4	$13.3M	Hold	150,000	–	–	7.46%	6
2019 Q3	$11.4M	Buy	150,000 +140,000	+1,400%	+$9.6M	8.77%	4
2019 Q2	$727K	Buy	+10,000	New	+$786K	0.56%	24

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

Paragon Associates & Paragon Associates II Joint Venture's ABBV Position: Q3 2020 in Review

Paragon Associates & Paragon Associates II Joint Venture sold out of AbbVie (ABBV) in Q3 2020, closing a stake of 60,000 shares — an estimated $5.89M sold.

Paragon Associates & Paragon Associates II Joint Venture first reported a position in ABBV in Q2 2019 and held it in 4 quarters. The position peaked at $13.3M in Q4 2019. 2,367 funds tracked by Wall St. Rank hold ABBV as of Q3 2020.

Paragon Associates & Paragon Associates II Joint Venture reported no remaining AbbVie position as of Q3 2020 after selling out during the quarter.
Paragon Associates & Paragon Associates II Joint Venture sold 60,000 AbbVie shares in Q3 2020, an estimated $5.89M.
Paragon Associates & Paragon Associates II Joint Venture first reported a position in AbbVie in Q2 2019 and held it in 4 quarters.
Paragon Associates & Paragon Associates II Joint Venture's AbbVie position peaked at $13.3M in Q4 2019.
2,367 funds tracked by Wall St. Rank held AbbVie as of Q3 2020.

Based on Paragon Associates & Paragon Associates II Joint Venture's 13F filing for Q3 2020, filed 13 Nov 2020.